Lower-Body Strength Relationships with Sprint, Jump, and Sport-Specific Skill Performance in High School Girls Softball Players

International Journal of Exercise Science 17(4): 86-98, 2024. Softball athletes require multiple fitness traits (e.g., strength, speed, power) and sport-specific skills (e.g., hitting, throwing) for success. Lower-body strength could underpin these qualities; this has received little analysis among high school female athletes. This research investigated correlations between absolute and relative lower-body strength with age, linear speed, lower-body power, and throwing and hitting velocity in high school girls softball athletes. Archival data collected from 34 high school girls softball players (age=14.91±1.00 years; height=1.66±0.07 m; body mass=63.21±9.59 kg) from a private strength and conditioning facility was analyzed. The data included: age, height, and body mass; 0-9.14 and 0-18.29 m sprint interval times; standing broad jump (SBJ) distance (lower-body power); batted ball exit (i.e., hitting) and throwing velocity; and absolute and relative three-repetition maximum (3RM) front squat and hexagonal bar deadlift (HBD). Pearson’s correlations (p\u3c0.05) derived relationships between absolute and relative strength with the fitness and sport-specific tests. The results indicated significant relationships between the 3RM HBD with age (r=0.389) and hitting velocity (r=0.418). The 3RM front squat related to the SBJ (r=0.422) and hitting velocity (r=0.457). Relative 3RM HBD correlated with the 0-18.29 m sprint interval (r=–0.349). These results suggested that a strength and conditioning program that improves the lower-body strength of high school girls softball players could contribute to faster sprinting speed, further horizontal jumps, and greater hitting velocity. The results from this study highlights the value of strength enhancement in high school girls softball athletes and provides support for strength and conditioning program provision for these individuals

A Preliminary Comparison of Firefighter Candidates\u27 Biddle Physical Ability Test Performance and Success Based on Training Class Participation

International Journal of Exercise Science 15(4): 1627-1640, 2022. The Biddle Physical Ability Test (BPAT) was developed to identify candidates who possess the physical ability to become structural firefighters. The test must be completed in ≤ 9:34 min:s before a candidate is admitted to an academy. Some community colleges offer semester-long training classes for candidates. This study analyzed whether candidates who completed a training class could perform the BPAT more effectively. Retrospective analysis of 30 males and 2 females who attempted the BPAT was conducted. BPAT tasks were: dry and charged hose drag; halyard raise, roof walk, and attic crawl; roof ventilation and victim removal; ladder removal and carry; stair climb with hose bundle; crawling search and tower exit; stair climb with air bottles; hose hoist; and return to ground floor with air bottles. Independent samples t-tests or Mann-Whitney U tests (p \u3c 0.05) and effect sizes calculated BPAT time differences between candidates who completed a training class or not. Twenty-nine candidates passed the BPAT; 6 completed a training class. The 3 candidates (2 males, 1 female) who failed did not complete a class. There were no significant between-group differences in BPAT times (p = 0.054-0.829). There were moderate effects for faster roof ventilation and victim removal, ladder removal and carry, and hose hoist times for candidates who attended a class (d = 0.74-0.95). While training classes may not be necessary for all candidates, physically demanding BPAT tasks were finished faster by candidates who completed a class. For candidates who find the BPAT physicality difficult, participation in a task-specific fitness and skills class may prove beneficial

ODNOSI IZMEĐU MIŠIĆNE SNAGE I MOĆI, I BRZINE BACANJA KOD VATERPOLISTA SREDNJOŠKOLACA NAKON BLOKA TRENINGA SNAGE

A high school strength and conditioning program should ideally improve fitness and develop sport-specific motor skills in athletes. This could be a targeted goal if research details relationships between sport-specific motor skills and measures of fitness in high school athletes. The aim of this study was to investigate the relationships between throwing velocity with muscular strength and power in boys high school water polo athletes after a 4-week resistance training block targeting strength. Eighteen athletes from one high school were recruited. Age, height, and body mass were recorded prior to training. Performance testing occurred in one day after the 4-week training block; strength was measured using combined handgrip strength from both hands and isometric lower-body strength via a leg/back dynamometer. Power was measured by a countermovement jump and 2-kg seated medicine ball throw. As a motor skill metric, participants maximally threw a water polo ball to measure throwing velocity. Partial correlations and stepwise regression controlling for age calculated relationships between throwing velocity with handgrip strength, leg/back strength, the countermovement jump, and medicine ball throw (p<0.05). Combined handgrip strength (r=0.712), leg/back strength (r=0.656), and the medicine ball throw (r=0.684) all showed significant positive relationships with throwing velocity. Age and combined handgrip strength predicted throwing velocity with 61.3% explained variance (r2=0.658, p<0.001). The data indicated that throwing velocity significantly related to handgrip and leg/back strength and upper-body power (measured by the medicine ball throw). As the program targeted these qualities, this could have influenced the relationships with the sport-specific motor skill of throwing.Program snage i kondicije namenjen srednjoškolcima bi idealno trebalo da poboljša kondiciju i razvije motoričke veštine specifične za sport kod sportista. Za ovaj problem bi se moglo naći rešenje ukoliko bi istraživanja detaljno opisala odnose između motoričkih veština specifičnih za sport i kondiciju sportista srednoškolaca. Cilj ovog istraživanja bio je da se ispita odnos između brzine bacanja sa mišićnom snagom i silom kod vaterpolista srednjoškolaca nakon 4-nedeljnog treninga otpora koji je ciljao snagu. Regrutovano je osamnaest sportista iz jedne srednje škole. Starost, visina i telesna masa zabeleženi su pre treninga. Testiranje učinka obavljeno je u jednom danu nakon blok treninga u trajanju od 4 nedelje; snaga je merena korišćenjem kombinovanom snagom stiska obe šake i izometrijske snage donjeg dela tela upotrebom dinamometra nogu/leđa. Sila je merena skokom iz počučnja i bacanjem medicinske lopte od 2 kg sedeći. Radi merenja motoričke veštine, učesnici su maksimalno bacali vaterpolo loptu da bi se izmerila brzina bacanja. Delimične korelacije i kontrola stepena regresije za odnose izračunate su prema uzrastu između brzine bacanja sa snagom stiska, snagom nogu/leđa, skoka iz počučnja i bacanja medicinske lopte (p<0,05). Kombinovana snaga stiska (r=0,712), sila nogu/leđa (r=0,656) i bacanje medicinske lopte (r=0,684) pokazali su značajnu pozitivnu vezu sa brzinom bacanja. Starost i kombinovana snaga stiska predviđaju brzinu bacanja sa 61,3% objašnjene varijanse (r2=0,658, p<0,001). Rezultati su pokazali da je brzina bacanja značajno povezana sa snagom stiska i nogu/leđa i snagom gornjeg dela tela (mereno bacanjem medicinske lopte). Pošto je program ciljao ove kvalitete, mogao bi uticati na odnose sa motoričkom veštinom bacanja koja je specifična za sport

Relationships Between Physical Ability Test Performance and Fitness in Recruits From a Southeastern U.S. Police Department

Police recruit occupational ability may be predicted by a physical ability test (PAT). This study determined relationships between a department-specific PAT and fitness test performance among police recruits. Retrospective analysis was conducted on recruit data (1,069 men and 404 women) from one department collected during 2005–2009 and 2016–2020. The following data were provided: grip strength; sit-and-reach; 60-second push-ups; 60-second sit-ups; 2.4-km run; and the PAT. The PAT involved exiting a vehicle and opening the trunk; running ;201 m; completing an obstacle course; dragging a 68-kg dummy 31 m; completing an obstacle course and running ;201 m; dry firing a weapon 6 times with each hand; and trunk item placement and vehicle reentry. Relationships between the PAT and fitness tests were measured by partial correlations and stepwise linear regression, both controlling for sex. The PAT was completed in a mean time of 4:1661:07 minutes : seconds. The PAT significantly (p,0.001) related to all fitness tests. Moderate relationships were found for push-ups (r520.35), sit-ups (r520.41), and the 2.4-km run (r 5 20.43). Small relationships were found with grip strength (r 5 20.19) and the sit-and-reach (r 5 20.17). The final regression model, which included sex and all fitness tests except the sit-and-reach, explained ;53% of the variance. Sex and the 2.4-km run explained;47% of the variance. Aerobic fitness appeared to have the greatest impact on PAT performance, which may have related to the PAT design and duration. Tasks completed in succession, and the use of a relatively light dummy, may stress aerobic fitness and muscular endurance to a greater extent

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

BackgroundSparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis.MethodsPROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin–angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850.FindingsBetween Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (−42·8%, 95% CI −49·8 to −35·0, with sparsentan versus −4·4%, −15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals.InterpretationOver 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis. Methods PROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin–angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850. Findings Between Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (−42·8%, 95% CI −49·8 to −35·0, with sparsentan versus −4·4%, −15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals. Interpretation Over 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function.</p